Faculty Presentations
Antonio Anzueto, MD |
Fig. 01 -
Title Slide
Fig. 02 -
Disclosures
Fig. 03 -
Definition - 2011
Fig. 04 -
Definition - 2017
Fig. 05 -
Beyond Variations
Fig. 06 -
Consequences
Fig. 07 -
Morbidity and Mortality
Fig. 08 -
Severe Exacerbations
Fig. 09 -
Mild
Fig. 10 -
Moderate and Severe
Fig. 11 -
Table 5.1.
Fig. 12 -
Etiology
Fig. 13 -
Bacterial Load
Fig. 14 -
Table 5.2.
Fig. 15 -
Treatment Options
Fig. 16 -
Photo
Fig. 17 -
Discolored Sputum
Fig. 18 -
Antibiotic Therapy
Fig. 19 -
Controlled Trial
Fig. 20 -
Steroid Use
Fig. 21 -
Prednisone
Fig. 22 -
Eosinophils
Fig. 23 -
Eosinophils (cont.)
Fig. 24 -
B Agonists
Fig. 25 -
Hospitalized Patients
Fig. 26 -
Table 5.4.
Fig. 27 -
Use NIV !!
Fig. 28 -
Table 5.5.
Fig. 29 -
Noninvasive and Conventional
Fig. 30 -
Table 5.6.
Fig. 31 -
Discharge Criteria
Fig. 32 -
Pulmonary Rehabilitation
Fig. 33 -
Weekly Comparisons
Fig. 34 -
Table 5.8.
Fig. 35 -
Bud / Form
Fig. 36 -
Fluticasone / Sal
Fig. 37 -
Corticosteroids
Fig. 38 -
Anticholinergic
Fig. 39 -
LABA / LAA
Fig. 40 -
Key Point Selection
Fig. 41 -
Management Key Points
Fig. 42 -
Management Key Points (Cont.)
TODO, let Pete know of any updates to this content
Six (6) provocative statements concerning clinical treatment of IBD. Each statement is presented as 5 steps:Step 1: the statement & introduction, + 5 possible opinions of that statement -- please choose one
Step 2: a graph of an international survey’s opinions of that statement
Step 3: a literature review for that statement
Step 4: a graph comparing the faculty's vs an international survey’s opinions, + faculty discussion
Step 5: a brief faculty summary, plus the list of references.
Please click on any Statement or any Step tab to read this publication in the order you prefer.